title: IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice.
abstract: The toxicity and antitumor efficacy of simian IL-15 was compared with human IL-2 in the context of syngeneic BMT. Groups of mice receiving or not receiving anti-CD3 activated splenocytes, termed "T-activated killer" (T-AK) cells, were treated between days 7 and 12 with escalating doses of IL-2 or IL-15 given twice daily. Recipients of IL-2+T-AK or IL-15+T-AK had significantly higher survival rates than saline+T-AK. Tissues from IL-2+T-AK, but not IL-15+Y-AK, treated mice revealed the presence of perivascular infiltrates in the lung and liver consisting of CD8+ T cells and Mac-1+ cells. Our findings demonstrate that IL-15 can be used effectively to stimulate antitumor responses post-BMT and may be associated with less toxicity than IL-2.
authors.affiliation: Department of Pediatrics and Medicine, University of Minnesota, Minneapolis 55455, USA.
authors.forename: E
authors.initials: E
authors.lastname: Katsanis
authors.forename: Z
authors.initials: Z
authors.lastname: Xu
authors.forename: A
authors.initials: A
authors.lastname: Panoskaltsis-Mortari
authors.forename: D J
authors.initials: DJ
authors.lastname: Weisdorf
authors.forename: M B
authors.initials: MB
authors.lastname: Widmer
authors.forename: B R
authors.initials: BR
authors.lastname: Blazar
mesh_terms: D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive; D019409:Interleukin-15 / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000187:drug effects / Q000637:transplantation; D016393:Lymphoma, B-Cell / Q000628:therapy*; D016853:Muromonab-CD3 / Q000494:pharmacology
chemical_list: D007155:Immunologic Factors; D019409:Interleukin-15; D007376:Interleukin-2; D016853:Muromonab-CD3